Operating Margin: 16.03%
Is the operating margin high or low?
The operating margin of 16.03% is 35% above its 5-year average of 11.87%, near the high end of its 5-year range (-8.92%–20.87%).
As of Thursday, June 25, 2026. 6.39% below its 12-month average of 17.12%.
PODD Operating Margin
Reported quarterly operating margin; no daily interpolation.
PODD Average Operating Margin Chart
PODD Current vs Average Operating Margin Chart
PODD Operating Margin Metrics
OPERATING MARGIN
16.03%
OPERATING MARGIN AVG TTM
17.12%
OPERATING MARGIN AVG 3Y
14.87%
OPERATING MARGIN AVG 5Y
12.91%
OPERATING MARGIN AVG 10Y
7.24%
OPERATING MARGIN AVG 15Y
0.35%
OPERATING MARGIN AVG 20Y
-4.76%
CURRENT VS TTM AVG
-6.39%
CURRENT VS 3Y AVG
+7.82%
CURRENT VS 5Y AVG
+24.20%
CURRENT VS 10Y AVG
+121.27%
CURRENT VS 15Y AVG
+4544.31%
CURRENT VS 20Y AVG
+436.67%
PODD Competitors' Operating Margin
| NAME | MARKET CAP | OPERATING MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Insulet Corp. (PODD) | $10.65B | 16.03% | 17.12% | 14.87% | 12.91% |
| Walgreens Boots Alliance, Inc. (WBA)vs › | $10.37B | -2.02% | -7.24% | -2.92% | -1.15% |
| Charles River Laboratories International, Inc. (CRL)vs › | $10.25B | 11.77% | 9.13% | 12.39% | 13.51% |
| Baxter International Inc. (BAX)vs › | $11.13B | -2.65% | -1.31% | -6.02% | 0.15% |
| Molina Healthcare, Inc. (MOH)vs › | $11.26B | 1.16% | 2.96% | 3.72% | 4.01% |
| Henry Schein, Inc. (HSIC)vs › | $9.53B | 5.60% | 5.75% | 6.18% | 6.20% |
| Align Technology, Inc. (ALGN)vs › | $12.58B | 14.44% | 15.23% | 16.08% | 17.45% |
| Revvity, Inc. (RVTY)vs › | $12.67B | 12.41% | 13.70% | 16.38% | 21.25% |
| Bio-Rad Laboratories, Inc. (BIO)vs › | $8.06B | 9.25% | 10.48% | 12.70% | 14.08% |
| Solventum Corporation (SOLV)vs › | $13.49B | 25.54% | 19.38% | 20.05% | 20.47% |
Operating Efficiency
Gross Margin
71.0%
Operating Margin
16.0%
Operating Margin Formula & Definition
Operating Margin = Operating Income / Revenue
Operating margin is the percentage of revenue remaining after operating expenses, reflecting operating efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Operating Margin FAQ
- What is the operating margin for Insulet Corp. (PODD)?
- The operating margin for PODD stock is 16.03%.
- Is Insulet Corp.'s operating margin high or low?
- The operating margin of 16.03% is 35% above its 5-year average of 11.87%, near the high end of its 5-year range (-8.92%–20.87%).
- What is the TTM average operating margin for Insulet Corp. (PODD)?
- The TTM average operating margin for PODD stock is 17.12%.
- What is the 3Y average operating margin for Insulet Corp. (PODD)?
- The 3Y average operating margin for PODD stock is 14.87%.
- What is the 5Y average operating margin for Insulet Corp. (PODD)?
- The 5Y average operating margin for PODD stock is 12.91%.
- What is the 10Y average operating margin for Insulet Corp. (PODD)?
- The 10Y average operating margin for PODD stock is 7.24%.
- What is the 15Y average operating margin for Insulet Corp. (PODD)?
- The 15Y average operating margin for PODD stock is 0.35%.
- What is the 20Y average operating margin for Insulet Corp. (PODD)?
- The 20Y average operating margin for PODD stock is -4.76%.
PODD Operating Margin History
| DATE | OPERATING MARGIN |
|---|---|
| 2026-03-31 | 16.03% |
| 2025-12-31 | 18.67% |
| 2025-09-30 | 16.66% |
| 2025-06-30 | 18.66% |
| 2025-03-31 | 15.61% |
| 2024-12-31 | 18.29% |
| 2024-09-30 | 16.20% |
| 2024-06-30 | 11.16% |
| 2024-03-31 | 12.88% |
| 2023-12-31 | 20.87% |
| 2023-09-30 | 12.66% |
| 2023-06-30 | 7.84% |
| 2023-03-31 | 7.74% |
| 2022-12-31 | 6.36% |
| 2022-09-30 | 0.85% |
| 2022-06-30 | -8.92% |
| 2022-03-31 | 12.83% |
| 2021-12-31 | 16.15% |
| 2021-09-30 | 12.23% |
| 2021-06-30 | 9.99% |
| 2021-03-31 | 6.46% |
| 2020-12-31 | -2.97% |
| 2020-09-30 | 10.17% |
| 2020-06-30 | 12.15% |
| 2020-03-31 | 3.79% |
| 2019-12-31 | 8.66% |
| 2019-09-30 | 8.85% |
| 2019-06-30 | 4.29% |
| 2019-03-31 | 4.58% |
| 2018-12-31 | 9.84% |
| 2018-09-30 | 4.54% |
| 2018-06-30 | 3.48% |
| 2018-03-31 | 0.00% |
| 2017-12-31 | -0.59% |
| 2017-09-30 | 1.68% |
| 2017-06-30 | -3.06% |
| 2017-03-31 | -5.22% |
| 2016-12-31 | -3.99% |
| 2016-09-30 | 2.55% |
| 2016-06-30 | -1.47% |
| 2016-03-31 | -9.48% |
| 2015-12-31 | -24.01% |
| 2015-09-30 | -16.95% |
| 2015-06-30 | -18.60% |
| 2015-03-31 | -11.87% |
| 2014-12-31 | -3.11% |
| 2014-09-30 | -3.84% |
| 2014-06-30 | -7.33% |
| 2014-03-31 | -2.73% |
| 2013-12-31 | 0.30% |
| 2013-09-30 | -28.33% |
| 2013-06-30 | -9.69% |
| 2013-03-31 | -10.82% |
| 2012-12-31 | -10.52% |
| 2012-09-30 | -15.47% |
| 2012-06-30 | -20.61% |
| 2012-03-31 | -22.81% |
| 2011-12-31 | -22.27% |
| 2011-09-30 | -21.90% |
| 2011-06-30 | -46.30% |
| 2011-03-31 | -25.74% |
| 2010-12-31 | -35.02% |
| 2010-09-30 | -32.52% |
| 2010-06-30 | -43.16% |
| 2010-03-31 | -51.57% |
| 2009-12-31 | -59.19% |
| 2009-09-30 | -71.95% |
| 2009-06-30 | -112.51% |
| 2009-03-31 | -140.12% |
| 2008-12-31 | -230.64% |
| 2008-09-30 | -196.18% |
| 2008-06-30 | -298.49% |
| 2008-03-31 | -299.99% |
| 2007-12-31 | -368.13% |
| 2007-09-30 | -384.65% |
| 2007-06-30 | -386.33% |
| 2007-03-31 | -537.75% |
| 2006-12-31 | -560.51% |
| 2006-09-30 | -1414.39% |
| 2006-06-30 | 100.00% |
| 2006-03-31 | 100.00% |
| 2005-12-31 | 0.00% |
| 2005-09-30 | 0.00% |
| 2005-06-30 | 0.00% |
| 2005-03-31 | 0.00% |
About Insulet Corp.
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Ashley A. McEvoy